Editorial. The Eleventh Hour: Neurosyphilis, Still Fashionable but a Controversial Diagnosis

<abstract xmlns="http://www.w3.org/1999/xhtml"> Lactic acidosis (LA) in end-stage liver disease (ESLD) patients has been recognized as one of the most complicated clinical problems and is associated with increased morbidity and mortality. Multiple-organ failure, associated with advanced stages of cirrhosis, exacerbates dysfunction of numerous parts of lactate metabolism cycle, which manifests as increased lactate production and impaired clearance, leading to severe LA-induced acidemia. These problems become especially prominent in ESLD patients, that undergo partial hepatectomy and, particularly, liver transplantation. Perioperative management of LA and associated severe acidemia is an inseparable part of anesthesia, post-operative and critical care for this category of patients, presenting a wide variety of challenges. In this review, lactic acidosis applied pathophysiology, clinical implications for ESLD patients, diagnosis, role of intraoperative factors, such as anesthesia- and surgery-related, vasoactive agents impact, and also current treatment options and modalities have been discussed.</abstract>

Review. Perioperative Management of Lactic Acidosis in End-Stage Liver Disease Patient

<abstract xmlns="http://www.w3.org/1999/xhtml"> Sepsis associated coagulopathy is due to the inflammation-induced activation of coagulation pathways concomitant with dysfunction of anticoagulant and fibrinolytic systems, leading to different degrees of haemostasis dysregulation. This response is initially beneficial, contributing to antimicrobial defence, but when control is lost coagulation activation leads to widespread microvascular thrombosis and subsequent organ failure. Large clinical trials of sepsis-related anticoagulant therapies failed to show survival benefits, but posthoc analysis of databases and several smaller studies showed beneficial effects of anticoagulants in subgroups of patients with early sepsis-induced disseminated intravascular coagulation. A reasonable explanation could be the difference in timing of anticoagulant therapy and patient heterogeneity associated with large trials. Proper selection of patients and adequate timing are required for treatment to be successful. The time when coagulation activation changes from advantageous to detrimental represents the right moment for the administration of coagulation-targeted therapy. In this way, the defence function of the haemostatic system is preserved, and the harmful effects of overwhelming coagulation activation are avoided.</abstract>

Review. Anticoagulant Therapy in Sepsis. The Importance of Timing

<abstract xmlns="http://www.w3.org/1999/xhtml"> The case of an 84 years old woman with uncharacteristic neurologic and cognitive symptoms, suspected of ischemic stroke is presented. Following an extensive assessment in the departments of neurology and internal medicine, the unusual aetiology of stroke was identified as meningovascular neurosyphilis. The patient fully recovered after antibiotic therapy. To our knowledge, this the eldest patient with tertiary neurosyphilis reported in the literature.</abstract>

Case report. Neurosyphilis Masquerading as Stroke in an 84-year-old

<abstract xmlns="http://www.w3.org/1999/xhtml"> Sepsis and septic shock are major healthcare problems, resulting in high morbidity and mortality. The Surviving Sepsis Campaign (SSC), which standardised the approach to sepsis, was recently updated. Strategies to decrease the systemic inflammatory response have been proposed to modulate organ dysfunctions. Endotoxin, derived from the membrane of Gram-negative bacteria, is considered a major factor in the pathogenesis of sepsis. Endotoxin adsorption, if effective, has the potential to reduce the biological cascade of Gram-negative sepsis.We present a case of a 64-year-old man with severe Gram-negative sepsis, following purulent peritonitis secondary to rectosigmoid adenocarcinoma. To reduce the amplitude of the general effects of endotoxins we used a novel device, the Alteco® LPS Adsorber (Alteco Medical AB, Lund, Sweden), for lipopolysaccharide (LPS) adsorption.The efficacy markers were: the overall haemodynamic profile, translated into decreased vasopressor requirements, the normalisation of the cardiac index, the systemic vascular resistance index combined with the lactate level and the reduction in procalcitonin (PCT) levels. A decrease in the sequential organ failure assessment (SOFA) score at twenty-four hours was demonstrated.The clinical course following treatment was favourable for the days immediately following the treatment.This was attributed to the removal of endotoxin from the systemic circulation. The patient died one week after the endotoxin removal session, developing an ischemic bowel perforation with subsequent multiple organ failures.</abstract>

Case Report. The Use of Endotoxin Adsorption in Extracorporeal Blood Purification Techniques. A Case Report

<abstract xmlns="http://www.w3.org/1999/xhtml"> The main complication of anticoagulant therapy is major bleeding. Clinicians are usually aware of these side effects and are careful when managing the therapeutic range of vitamin K antagonist drugs. But major bleeding, while lifethreatening, can be overlooked if there are no visible signs of bleeding. Two cases are described in which inaccurate diagnoses lead to inadequate treatment.</abstract>

Case Report. Non-Obvious, Post-Traumatic, Life-Threatening Bleeding in Two Elderly Patients

<abstract xmlns="http://www.w3.org/1999/xhtml"> Background: Newly approved immunotherapeutic agents, like CTLA-4 inhibitors and antibodies against PD-1, are a promising therapeutic option in cancer therapy.Case presentation: A 74-year-old man, with a history of advanced stage melanoma and treatment with ipilimumab, pembrolizumab and nivolumab, was admitted to the hospital due to respiratory failure with hypoxemia and dyspnoea. He rapidly developed severe acute respiratory distress syndrome (ARDS), which required treatment in the intensive care unit which included mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Computed tomographic imaging (CT) showed signs of a pneumonitis, with an ARDS pattern related to the use of PD-1 antibodies. Treating the patient with high-dose immunosuppressive steroids led to an overall improvement. He was transferred to a rehabilitation hospital and subsequently to his home.Discussion and conclusion: This is a unique case report of a patient suffering a grade 4 adverse event under nivolumab who survived having been treated with ECMO. It highlights the possibility of associated adverse reactions as well as the use of ECMO in palliative care patients. ECMO can be of great success even in patients with malignancies, but careful decision making should be done on a case by case basis.</abstract>

Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis

AHEAD OF PRINT

Volume 9 (2023): Issue 4 (October 2023)

Volume 9 (2023): Issue 3 (July 2023)

Volume 9 (2023): Issue 2 (April 2023)

Volume 9 (2023): Issue 1 (January 2023)

Volume 8 (2022): Issue 4 (October 2022)

Volume 8 (2022): Issue 3 (July 2022)

Volume 8 (2022): Issue 2 (April 2022)

Volume 8 (2022): Issue 1 (January 2022)

Volume 7 (2021): Issue 4 (October 2021)

Volume 7 (2021): Issue 3 (July 2021)

Volume 7 (2021): Issue 2 (April 2021)

Volume 7 (2021): Issue 1 (January 2021)

Volume 6 (2020): Issue 4 (October 2020)

Volume 6 (2020): Issue 3 (July 2020)

Volume 6 (2020): Issue 2 (April 2020)

Volume 6 (2020): Issue 1 (January 2020)

Volume 5 (2019): Issue 4 (October 2019)

Volume 5 (2019): Issue 3 (July 2019)

Volume 5 (2019): Issue 2 (April 2019)

Volume 5 (2019): Issue 1 (January 2019)

Volume 4 (2018): Issue 4 (October 2018)

Volume 4 (2018): Issue 3 (July 2018)

Volume 4 (2018): Issue 2 (April 2018)

Volume 4 (2018): Issue 1 (January 2018)

Volume 3 (2017): Issue 4 (October 2017)

Volume 3 (2017): Issue 3 (July 2017)

Volume 3 (2017): Issue 2 (April 2017)

Volume 3 (2017): Issue 1 (February 2017)

Volume 2 (2016): Issue 4 (October 2016)

Volume 2 (2016): Issue 3 (July 2016)

Volume 2 (2016): Issue 2 (April 2016)

Volume 2 (2016): Issue 1 (January 2016)

Volume 1 (2015): Issue 4 (October 2015)

Volume 1 (2015): Issue 3 (July 2015)

Volume 1 (2015): Issue 2 (April 2015)

Volume 1 (2015): Issue 1 (January 2015)

The Journal of Critical Care Medicine

The Journal of Critical Care Medicine aims to publish high quality double-blind peer-reviewed articles integrating a broad range of topics from the entire spectrum of Critical CareMedicine and related pathologies of critical care patients, including, but not restricted to general surgery, perioperative care, cardiology, internal medicine, pneumology, infectious diseases, organ transplantation, emergency medicine, pediatrics and neurology. Our journal’s scope is to provide for intensivists all around the world the newest information related to the critical ill patients, treatments and their outcomes.  The journal will consider for publication suitable articles offering new insights into pathophysiological mechanisms, diagnostic and treatment in critical care medicine, from basic to clinical academic research, including also relevant topics on biomedical research, health policy research, medical technology development and ethical concerns.  Publication fee  The publication fee for an accepted article is 250 EUR.  Why subscribe and read  The journal addresses the entire community of specialists involved in treating the critically illpatients, with a special focus on the scientific community from Central and Eastern European countries, aiming to provide studies on critical care medicine with a new regional perspective, specific for this part of Europe but not restricted to it. The journal will also publish international, overseas articles that would discuss current topics in peri-operative and critical care medicine, contributing to a better understanding of the pathologies leading to critical illnesses and reflecting international models of care for these conditions.  Why submit  The journal will stimulate publication of research that could be easily translated into clinical practice. The diversity of published articles, from "letter to editor" to most complex scientific research, will ensure various possibilities for knowledge dissemination. We encourage the use of open-access instrument ORCID ID for authors, which is also used by reviewers, and editorial board members. New accounts can be created manually or by retrieve the details from the ORCID registry   Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 